Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 1
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: ICOTREG
Page 1
Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study).
Mastrorosa I, Gagliardini R, Segala FV, Mondi A, Lorenzini P, Cerva C, Taddei E, Bai F, Vergori A, Marcantonio N, Pinnetti C, Cicalini S, Murri R, Mazzotta V, Camici M, Mosti S, Bini T, Maffongelli G, Beccacece A, Milozzi E, Iannetta M, Lamonica S, Fusto M, Plazzi MM, Ottou S, Lichtner M, Fantoni M, Andreoni M, Sarmati L, Cauda R, Girardi E, Nicastri E, D'Arminio Monforte A, Palmieri F, Cingolani A, Vaia F, Antinori A; ESCAPE study group. Mastrorosa I, et al. Among authors: antinori a. EClinicalMedicine. 2023 Mar 10;57:101895. doi: 10.1016/j.eclinm.2023.101895. eCollection 2023 Mar. EClinicalMedicine. 2023. PMID: 36936403 Free PMC article.
BACKGROUND: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of sarilumab. ...Overall, 39/121 (32%) AEs were reported in arm A and 14/55 (23%) in B (p = 0.195), while serious AEs were 22/121 (18%) and 7/55 …
BACKGROUND: Among interleukin-6 inhibitors suggested for use in COVID-19, there are few robust evidences for the efficacy of s …
Epidemiology of ventilator-associated pneumonia in ICU COVID-19 patients: an alarming high rate of multidrug-resistant bacteria.
Tetaj N, Capone A, Stazi GV, Marini MC, Garotto G, Busso D, Scarcia S, Caravella I, Macchione M, De Angelis G, Di Lorenzo R, Carucci A, Antonica MV, Gaviano I, Inversi C, Agostini E, Canichella F, Taloni G, Evangelista F, Onnis I, Mogavero G, Lamanna ME, Rubino D, Di Frischia M, Porcelli C, Cesi E, Antinori A, Palmieri F, D'Offizi G, Taglietti F, Nisii C, Cataldo MA, Ianniello S, Campioni P, Vaia F, Nicastri E, Girardi E, Marchioni L; ICU COVID-19 Study Group. Tetaj N, et al. Among authors: antinori a. J Anesth Analg Crit Care. 2022 Aug 19;2(1):36. doi: 10.1186/s44158-022-00065-4. J Anesth Analg Crit Care. 2022. PMID: 37386603 Free PMC article.
The aim of this study was to assess the incidence, antimicrobial resistance, risk factors, and outcome of VAP in ICU COVID-19 patients in invasive mechanical ventilation (MV). METHODS: Observational prospective study including adult ICU admissions between January 1, …
The aim of this study was to assess the incidence, antimicrobial resistance, risk factors, and outcome of VAP in ICU COVID-19 …
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV.
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, Meschi S, Iannazzo R, Mazzotta V, Colavita F, Mastrorosa I, Cimini E, Mariotti D, De Pascale L, Marani A, Gallì P, Garbuglia A, Castilletti C, Puro V, Agrati C, Girardi E, Vaia F, Antinori A; HIV-VAC study group. Vergori A, et al. Among authors: antinori a. Nat Commun. 2022 Aug 22;13(1):4922. doi: 10.1038/s41467-022-32263-7. Nat Commun. 2022. PMID: 35995780 Free PMC article.
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-gamma production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm(3) …
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we …
Neutralizing activity and T-cell response after bivalent fifth dose of messenger RNA vaccine in people living with HIV.
Vergori A, Matusali G, Lepri AC, Cimini E, Fusto M, Colavita F, Gagliardini R, Notari S, Mazzotta V, Mariotti D, Cicalini S, Girardi E, Vaia F, Maggi F, Antinori A; HIV-VAC Study group. Vergori A, et al. Among authors: antinori a. Int J Infect Dis. 2023 Sep;134:195-199. doi: 10.1016/j.ijid.2023.06.010. Epub 2023 Jun 19. Int J Infect Dis. 2023. PMID: 37343783 Free PMC article.
OBJECTIVES: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vaccine original/BA4/5 vaccine in people living with HIV (PLWH). METHODS: This is an observational cohort study to evaluate the outcomes of S …
OBJECTIVES: To investigate immunogenicity of SARS-CoV-2 vaccine third booster dose (3BD; fifth dose) with bivalent vacc …
Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia.
Vergori A, Lorenzini P, Cozzi-Lepri A, Donno DR, Gualano G, Nicastri E, Iacomi F, Marchioni L, Campioni P, Schininà V, Cicalini S, Agrati C, Capobianchi MR, Girardi E, Ippolito G, Vaia F, Petrosillo N, Antinori A, Taglietti F; ReCOVeRI Study Group. Vergori A, et al. Among authors: antinori a. Sci Rep. 2021 May 31;11(1):11334. doi: 10.1038/s41598-021-90713-6. Sci Rep. 2021. PMID: 34059708 Free PMC article.
Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The aim of this study was to evaluate whether the antinflammatory effects of pLMWH could translate in lower rate of clinical progression in pat …
Prophylactic low molecular weight heparin (pLMWH) is currently recommended in COVID-19 to reduce the risk of coagulopathy. The …
Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
Mazzotta V, Cozzi Lepri A, Colavita F, Rosati S, Lalle E, Cimaglia C, Paulicelli J, Mastrorosa I, Vita S, Fabeni L, Vergori A, Maffongelli G, Carletti F, Lanini S, Caraffa E, Milozzi E, Libertone R, Piselli P, Girardi E, Garbuglia A, Vaia F, Maggi F, Nicastri E, Antinori A; INMI COVID-19 Outpatient Treatment Study Group. Mazzotta V, et al. Among authors: antinori a. J Med Virol. 2023 Jan;95(1):e28186. doi: 10.1002/jmv.28186. Epub 2022 Oct 7. J Med Virol. 2023. PMID: 36184918 Free PMC article.
The efficacy on the Omicron variant of the approved early coronavirus disease-2019 (COVID-19) therapies, especially monoclonal antibodies, has been challenged by in vitro neutralization data, while data on in vivo antiviral activity are lacking. We assessed p …
The efficacy on the Omicron variant of the approved early coronavirus disease-2019 (COVID-19) therapies, especially mon …